CYP2D6 polymorphism in a Mexican American population

R. Mendoza, Yu-Jui Yvonne Wan, R. E. Poland, M. Smith, K. M. Lin

Research output: Contribution to journalArticle

Abstract

Despite being one of the fastest growing populations in America, pharmacogenetic data is largely unavailable for Mexican Americans. The CYP2D6 genotype and dextromethorphan hydroxylation phenotype was studied in 248 Mexican American subjects from Los Angeles County. The incidence of poor metabolizer phenotype was 3.0%, and the mean Log10 dextromethorphan/dextrorphan ratio was -2.47 indicating Mexican Americans have an increased metabolic rate when compared to published data on Caucasian and African American populations. The CYP2D6 genotype was analyzed by allele-specific PCR analysis for the presence of mutant or null alleles at the CYP2D6 locus. The CYP2D6*4 mutation allele gene frequency was 10.1% and the allelic frequency for the CYP2D6 duplication mutation was 1%. Four subjects were homozygous for the CYP2D6*4 mutation. The allelic frequency for the CYP2D6*10 mutation was 17.1%. Very few subjects were shown to possess the CYP2D6*3, CYP2D6*5, and CYP2D6*17 mutant alleles. A strong correlation between genotype and phenotype was present. The racial admixture in present day Mexican Americans, largely a blend of indigenous Indian groups of Mexico and Spanish genetic influences, is reflected in the results from our genotypic analysis.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'CYP2D6 polymorphism in a Mexican American population'. Together they form a unique fingerprint.

  • Cite this

    Mendoza, R., Wan, Y-J. Y., Poland, R. E., Smith, M., & Lin, K. M. (2001). CYP2D6 polymorphism in a Mexican American population. Clinical Pharmacology and Therapeutics, 69(2).